Abstract

Helper T cells (CD3+CD4+ T cells) and cytotoxic T cells (CD3+CD8+ T cells) play direct and indirect antiviral roles. This study retrospectively explored the clinical significance of peripheral lymphocytes, especially the dynamic analysis of T-cell subsets, in determining coronavirus disease 2019 (COVID-19) severity and progression. Seventy-nine patients with COVID-19 in the Public Health Clinical Center of Chengdu from January to February 2020 were included, 59 of which were analyzed for dynamic peripheral T-cell subsets expression. The neutrophil to CD4+ T lymphocyte ratio (N4R) and neutrophil to CD3+ T lymphocyte ratio (N3R) showed clinical significance in differentiating severe or critically-severe COVID-19, with area under receiver operating characteristic curves (AUCs) of 0.933 and 0.900, respectively (P < 0.05). COVID-19 patients with more baseline peripheral lymphocytes or NK cells were prone to test negative to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after therapy (P < 0.05), and the AUC of NK cells for predicting negative results of SARS-CoV-2 RNA detection after therapy was 0.800. When the number of peripheral CD3+CD4+ and CD3+CD8+ T cells in COVID-19 patients continuously increased 6-9 days after baseline, the period of disease exacerbation could be delayed for more than 2 weeks after admission. Baseline N4R and N3R could be potential biomarkers for assisting in differentiating COVID-19 severity, and dynamically monitoring peripheral CD3+CD4+ and CD3+CD8+ T cells 6-9 days after baseline could help clinicians to evaluate disease progression in COVID-19 patients.

Highlights

  • Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

  • The average age had an upward trend with the worsening of COVID-19 (P = 0.004)

  • This study focused on elucidating the dynamic characteristics of neutrophil, lymphocyte, and Tlymphocyte subsets in COVID-19 patients with different outcomes, and it was observed that the number of lymphocytes, CD3+ T cells, and CD3+CD4+ T cells in the stable and improved groups was significantly more than that in the exacerbated or dead group at baseline, 6-9 days after baseline, and 10-14 days after baseline (P < 0.05, Figure 2)

Read more

Summary

Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has rapidly spread globally and become a serious public health problem since its outbreak in December 2019. 223 countries/regions have been affected by this epidemic, and over 102 million people have been confirmed to have COVID-19, while more than 2 million have died. COVID-19 patients may have symptoms similar to the common cold or influenza, such as fever, cough, and fatigue, but their condition progresses quickly. Severe patients can appear short of breath and develop acute respiratory distress syndrome or organ failure, and some even die [1,2,3]. Monitoring COVID-19 severity is helpful in clinical decision making

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call